Tero
Aittokallio
InFLAMES Lippulaiva
dosentti, matemaattis-luonnontieteellinen tiedekunta
PhD
Linkit
Julkaisut
JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML (2015)
Blood
(Muu (O2))
Identification of drug candidates and repurposing opportunities through compound-target interaction networks (2015)
Expert Opinion on Drug Discovery
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites (2015)
Cancer Research
(Muu (O2))
Dasatinib and everolimus show synergistic growth inhibition with paclitaxel in an ovarian granulosa cell tumor model (2015)
Cancer Research
(Muu (O2))
Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors (2015)
Cancer Research
(Muu (O2))
Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling (2015)
Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
What is synergy? The Saariselka agreement revisited (2015)
Frontiers in Pharmacology
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Toward more realistic drug-target interaction predictions (2015)
Briefings in Bioinformatics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Patient-derived prostate cancer cells for piloting of drug sensitivity and resistance testing (2015)
BJU International
(Muu (O2))
Pro-apoptotic functions of AMPK revealed by Myc (2015)
Molecular Cancer Research
(Muu (O2))